Most of the literature out there about remdesivir was published in 2021 and 2022 and there hasn’t been much since, and almost every study has some kind of link to the NIH. I also find it odd that there’s been no retrospective since then. Of course, funding for studies usually comes from the NIH and Pharma (revolving door syndrome) and they certainly don’t want anyone studying how ineffective it’s been. Below is one report that seems to be from an independent group. You can decide if you think it’s more or less reliable.
Summary from the article:
“Martin Landray of the University of Oxford, who is co-leading the world’s largest study of various COVID-19 treatments, says remdesivir “definitely doesn’t work in the sickest patients where the biggest gains would be” but might help people at earlier stages of disease. Further complicating the matter, most people infected with SARS-CoV-2 recover without any intervention. “The argument that the earlier you use it the better is great until you realize what the implications of that are: You won’t save many lives, and you’ll have to treat a lot of patients,” Landray says. “It’s very inconvenient, and it’ll cost you a fortune.””
My opinion? Since remdesivir may be most helpful in the early stages of disease, take a bunch of ivermectin instead, since that’s when it’s most effective too. IVM has also been shown to be effective in the late stages of disease, unlike remdesivir.
I guess I pinged the right person. :) I actually saw that article and it was the best I could find. but appreciate your knowledge and confirmation I will send that along to the family. THANKS!!